A New York restaurant is offering a “teeny-weeny mini meal” for its customers on weight-loss jabs.

Once renowned for gargantuan portions, an increasing number of American establishments are shrinking their dishes to accommodate the dwindling appetites of people on GLP-1 drugs.

Among them is Clinton Hall, a craft beer and burger joint in New York. The bar introduced its “teeny-weeny mini meal,” a bite-sized burger and fries, alongside a small margarita, beer or wine, in April.

Aristotle Hatzigeorgiou, the restaurant’s owner, added the dish to his menu after seeing how many of his own friends’ appetites were shrinking owing to weight-loss drugs, and becoming worried about food waste.

“I am always with someone who is taking Ozempic, Mounjaro, one of those things,” he told the New York Times. “They have one or two bites of food and a couple of sips of drinks, and they’re done.”

It is estimated that up to 10 per cent of Americans are taking weight-loss drugs known as GLP-1s and more than 30 per cent have expressed interest in taking them.

The drugs work by dramatically reducing the user’s appetite, often resulting in rapid, significant weight loss.

“I was worried that as people’s belts were getting tighter, their wallets were also getting tighter,” Mr Hatzigeorgiou added.

‘Competitive advantage’

As the US tries to get to grips with obesity, the weight loss revolution is potentially bad news for the hospitality industry.

Earlier this year, Bloomberg Intelligence surveyed 1,000 GLP-1 users and found that 54 per cent of respondents were dining out far less than before.

Morgan Stanley found that two-thirds of weight-loss drug users were eating out less.

“It used to only be the ladies who ate like birds,” said Dana Gunders, president of ReFED, an organisation that works to address food waste told the New York Times.

“Now you have a whole new market segment that wants smaller portions actively. I think restaurants that see that as an opportunity and feed that group are going to have a competitive advantage.”